Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 20, 2014 07:30 ET | Source: Marina Biotech, Inc.

Marina Biotech Regains Compliance With Exchange Act Reporting Obligations

BOSTON, MA--(Marketwired - Aug 20, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced...
June 12, 2014 07:30 ET | Source: Marina Biotech, Inc.

Marina Biotech Announces That Licensee Mirna Therapeutics Enrolls First Patient in Hematologic Malignancy Cohort of On-Going Trial

BOSTON, MA--(Marketwired - Jun 12, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced...
June 05, 2014 07:30 ET | Source: Marina Biotech, Inc.

Marina Biotech Receives Decision to Grant Japanese Patent for Its SMARTICLES Nucleic Acid Delivery Technology

BOSTON, MA--(Marketwired - Jun 5, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that...
May 28, 2014 07:30 ET | Source: Marina Biotech, Inc.

Marina Biotech to Present at the LD Micro Invitational 2014

BOSTON, MA--(Marketwired - May 28, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that...
May 14, 2014 07:30 ET | Source: Marina Biotech, Inc.

Marina Biotech Provides Organizational Update

BOSTON, MA--(Marketwired - May 14, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today provided an...
May 06, 2014 07:30 ET | Source: Marina Biotech, Inc.

Marina Biotech Presents Clinical Data Demonstrating Delivery of Both Single and Double-Stranded Nucleic Acids to Tumors

BOSTON, MA--(Marketwired - May 6, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, presented data from...
April 02, 2014 09:08 ET | Source: Marina Biotech, Inc.

Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-Based Diagnostics and Therapeutics for Rare Diseases

PRINCETON, NJ and REHOVOT, ISRAEL and BOSTON, MA--(Marketwired - Apr 2, 2014) - Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and...
March 11, 2014 07:30 ET | Source: Marina Biotech, Inc.

Marina Biotech to Use Its RNAi, Antisense and microRNA Therapeutics Platform to Develop Drugs for Rare Diseases

BOSTON, MA--(Marketwired - Mar 11, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today...
February 27, 2014 07:30 ET | Source: Marina Biotech, Inc.

Marina Biotech Continues to Build Worldwide Patent Protection for Its SMARTICLES(R) Nucleic Acid Delivery Technology

BOSTON, MA--(Marketwired - Feb 27, 2014) - Marina Biotech, Inc. (OTC Pink: MRNA), a leading oligonucleotide-based drug discovery and development company focused on rare diseases, announced...
February 24, 2014 07:30 ET | Source: Marina Biotech, Inc.

Marina Biotech Announces $6 MM Convertible Preferred Stock Financing and Conversion to Common Stock of the Company's Promissory Note

BOSTON, MA--(Marketwired - Feb 24, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company focused on rare diseases, announced today...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right